PROLIA®


 
 
 
 
 
 
 
 
 


 

PROLIA® (Denosumab) is a RANKL inhibitor used for the treatment of various diseases of overactive bone resorption.

PROLIA® is manufactured by Amgen.

Administration and Dosage:

Administration of PROLIA® is by 1 subcutaneous injection every 6 months.

Common Side Effects:

The more common side effects of PROLIA® include serious allergic reactions; low blood calcium (hypocalcemia); severe jaw bone problems (osteonecrosis); unusual thigh bone fractures; increased risk of broken bones including bones in the spine, serious skin, lower stomach area, bladder, or ear infections; skin problems, and bone, joint, or muscle pain.

More Information:

Please read the full Prescribing Information and Medication Guide for PROLIA® and discuss any questions you have with your doctor.

Ready to Schedule an Appointment?

Please CLICK HERE to get started.

Indication:

PROLIA® is indicated to treat:

  • Postmenopausal Women with Osteoporosis at high risk for fracture
  • Men with Osteoporosis at high risk for fracture
  • Women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
  • Men at high risk for fracture receiving therapy for nonmetastatic prostate cancer
  • Glucocorticoid induced osteoporosis in men and women at high risk for fracture